DOWNSTREAM PROCESSING FEATURED ARTICLES
The Benefits Of Genderless Sterile Connectors For Single-Use Applications
Genderless connections are those in which the connector halves are identical in design, thus eliminating the need for different male and female halves to make the connection.
-
Millipore Unveils Mobius FlexReady Solutions At INTERPHEX 2009 Billerica, Massachusetts-Millipore Corporation, a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, announces the launch of its Mobius FlexReady Solutions.
-
Combination Sterile Connections For Single-Use Applications
Gain insight into why combination connections are used in single-use bioprocessing and guidance on how single-use systems can be designed to integrate the combination connectors.
-
Antibody Evolution Could Guide HIV Vaccine Development
Observing the evolution of a particular type of antibody in an infected HIV-1 patient, a study spearheaded by Duke University, including analysis from Los Alamos National Laboratory, has provided insights that will enable vaccination strategies that mimic the actual antibody development within the body.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Sani-Tech® Ultra White Paper
For several years, pharmaceutical manufacturing professionals have increasingly stated concerns about material leachables and extractables and their impact on the products they produce. Fluid transfer systems that include flexible tubing have been at the forefront of this discussion.
-
Global Biochemical Profiling For Bioprocess Optimization
It is widely understood that the production phase of bioprocessing can have a significant impact on the overall profitability of the biopharmaceutical.
-
Selecting The Optimal Resins For Endotoxin Depletion In Process Purification
A guide to effectively remove endotoxins with versatile process resins.
-
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media
Monoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
-
Examining Column Reproducibility During Method Development In Clinical Labs
In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.
-
Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode Chromatography
The first step in purification of an important class of therapeutic proteins, the polyclonal or monoclonal antibodies (mAbs), is their capture from plasma or tissue culture supernatants. Protein A–based media are by far the most common class of affinity products used for this purpose.